


Falsified Medicines Directive in Europe



The Falsified Medicines Directive in Europe


Overview of the legislative process



National Medicines Verification Organization and National Medicines Verification System



Successful & timely local stakeholder engagement is mission critical



Adapted from the Pan-European Structure presented by the EMVO



Scope and High-Level Requirements



1

Safety Features

- **Unique Identifier (UI):** GS1 DataMatrix with GTIN, Serial Number, Expiry Date and Batch number)
- **Anti-Tampering Device (ATD):** tamper evidence label or glued carton



Standard Product Identification, GTIN
Standard data carrier : 2D Matrix Code

2

Upload of Data to Repositories

- All data included in the Unique Identifier and additional product master data attributes

Manufacturers



28 national Databases;
Choice for National organizations with only 2 IT providers

3

Verification and Decommissioning




- Verification by manufacturers, wholesalers, pharmacies, hospitals
- Decommissioning by Hospitals and Pharmacies

Improves reliability in the supply chain



The FMD also defines the governance model




European Medicines Verification Organisation (EMVO) will

- Establish, manage and operate **European Hub**
- Ensure **interoperability** of connected systems
- Conclude **agreements** with NMVOs
- Set **standards** for the EMVS
- **Manage** ‘national Blueprint’ systems at request of national stakeholders

National stakeholders govern national systems through National Medicines Verification Organisation (NMVO)

- Establish and manage **national** system
- **Ensure interoperability** with European Hub
- Conclude **agreements** with EMVO
- Analyse exceptional events at national level

Milestones for National Medicines Verification Organisation




FMD went live on time, i.e. on February 9th, 2019




- This the beginning of a journey, a lot of activities need still to be performed:
 - Connections of Industries : 965 connected out of 1600 expected
 - Connections of wholesalers, hospitals and pharmacies
 - Alert Handling
 - Report to Health Authorities

OVERVIEW OF ALERTS AND SCANS IN ALL COUNTRIES



END-USERS CONNECTION OVERVIEW(*)



Continuous Information by National Medicines Verification Organisations

Internet Site



News

Announcement of extension to FMD 'use and learn' period in Ireland beyond September
2nd September 2019



Protecting Irish patients from falsified medicines

The Irish Medicines Verification Organisation (IMVO) is a new organisation set up to protect Irish patients from the threat of falsified medicines being supplied through legitimate channels.




Latest news

Newsletter 4 September 2019: the national self-assessment tool; what you can do yourself to prevent scanning problems; new date for the webinar.
September 4, 2019



According to the FiMVO 2020 budget, the current estimate for the operational fees payable to the Finnish Medicines Verification Organisation in 2020 will be 5 000 euro/MAH. Please note that this remains an estimate until the number of MAHs can be confirmed at the end of 2019.

Type of potential secondary use opportunities of EMVS *



* Subject to compliance safeguards or adoption of an appropriate regulatory basis as required.

FMD : an initiative to protect the European pharmaceutical supply chain from the entry of falsified medicines

Success Key Criteria:

- ❖ Compliance to international standards (GS1)
- ❖ Interoperability of systems
- ❖ Cooperation and Collaboration of all stakeholders

*Doing now what patients
need next*